BAUSCH HEALTH COMPANIES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.95 USD | -1.14% |
|
-14.09% | -13.34% |
| May. 03 | RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform | MT |
| May. 02 | Bausch Health Shares Fall Following Q1 Results | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 10,545 | 7,385 | 9,921 | 2,273 | 2,929 | 2,549 | - | - |
| Enterprise Value (EV) 1 | 33,196 | 29,494 | 30,456 | 2,273 | 2,929 | 22,986 | 21,638 | 2,549 |
| P/E ratio | -5.89 x | -13.2 x | -10.5 x | -10.1 x | -4.95 x | 20.6 x | 6.6 x | 5.89 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.23 x | 0.92 x | 1.18 x | 0.28 x | 0.33 x | 0.27 x | 0.26 x | 0.26 x |
| EV / Revenue | 3.86 x | 3.67 x | 3.61 x | 0.28 x | 0.33 x | 2.45 x | 2.24 x | 0.26 x |
| EV / EBITDA | 9.3 x | 8.95 x | 8.77 x | 0.75 x | 0.97 x | 7.34 x | 6.67 x | 0.72 x |
| EV / FCF | 27 x | 36.5 x | 26.3 x | -2.4 x | 3.58 x | 22.1 x | 16.1 x | - |
| FCF Yield | 3.71% | 2.74% | 3.8% | -41.6% | 27.9% | 4.53% | 6.23% | - |
| Price to Book | 9.92 x | 13.8 x | - | - | - | -2.9 x | -7.47 x | - |
| Nbr of stocks (in thousands) | 352,431 | 355,053 | 359,331 | 361,868 | 365,195 | 366,797 | - | - |
| Reference price 2 | 29.92 | 20.80 | 27.61 | 6.280 | 8.020 | 6.950 | 6.950 | 6.950 |
| Announcement Date | 2/19/20 | 2/24/21 | 2/23/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8,601 | 8,027 | 8,434 | 8,124 | 8,757 | 9,396 | 9,665 | 9,996 |
| EBITDA 1 | 3,571 | 3,294 | 3,472 | 3,022 | 3,014 | 3,131 | 3,246 | 3,541 |
| EBIT 1 | 3,226 | 2,959 | 2,951 | 2,775 | 2,808 | 3,019 | 3,145 | 3,459 |
| Operating Margin | 37.51% | 36.86% | 34.99% | 34.16% | 32.07% | 32.13% | 32.54% | 34.61% |
| Earnings before Tax (EBT) 1 | -1,837 | -934 | -1,024 | -129 | -390 | 184.4 | 452.7 | 522.1 |
| Net income 1 | -1,788 | -560 | -948 | -225 | -592 | 148.2 | 389.2 | 431.7 |
| Net margin | -20.79% | -6.98% | -11.24% | -2.77% | -6.76% | 1.58% | 4.03% | 4.32% |
| EPS 2 | -5.080 | -1.580 | -2.640 | -0.6200 | -1.620 | 0.3367 | 1.053 | 1.180 |
| Free Cash Flow 1 | 1,231 | 809 | 1,157 | -946 | 817 | 1,041 | 1,348 | - |
| FCF margin | 14.31% | 10.08% | 13.72% | -11.64% | 9.33% | 11.07% | 13.94% | - |
| FCF Conversion (EBITDA) | 34.47% | 24.56% | 33.32% | - | 27.11% | 33.23% | 41.52% | - |
| FCF Conversion (Net income) | - | - | - | - | - | 701.95% | 346.32% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/19/20 | 2/24/21 | 2/23/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,196 | 1,918 | 1,967 | 2,046 | 2,193 | 1,944 | 2,167 | 2,238 | 2,408 | 2,153 | 2,340 | 2,415 | 2,504 | 2,250 | 2,425 |
| EBITDA 1 | 909 | 732 | 701 | 766 | 823 | 588 | 727 | 830 | 869 | 665 | 769 | 835.6 | 862 | 771.5 | 834.8 |
| EBIT 1 | 773 | 618 | 587 | 668 | 771 | 494 | 651 | 747 | 812 | 568 | 755.8 | 825 | 879 | 720.9 | 817.2 |
| Operating Margin | 35.2% | 32.22% | 29.84% | 32.65% | 35.16% | 25.41% | 30.04% | 33.38% | 33.72% | 26.38% | 32.3% | 34.16% | 35.1% | 32.05% | 33.69% |
| Earnings before Tax (EBT) 1 | 21 | -82 | -129 | 439 | -357 | -136 | 79 | -326 | -7 | -69 | 28.4 | 91.65 | 133.3 | 77 | 139.4 |
| Net income 1 | 69 | -69 | -145 | 399 | -410 | -201 | 26 | -378 | -39 | -64 | -24 | 47 | 98 | - | - |
| Net margin | 3.14% | -3.6% | -7.37% | 19.5% | -18.7% | -10.34% | 1.2% | -16.89% | -1.62% | -2.97% | -1.03% | 1.95% | 3.91% | - | - |
| EPS 2 | 0.1900 | -0.1900 | -0.4000 | 1.100 | -1.130 | -0.5500 | 0.0700 | -1.030 | -0.1100 | -0.1700 | -0.005000 | 0.1350 | 0.2250 | 0.1500 | 0.2700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/23/22 | 5/10/22 | 8/9/22 | 11/3/22 | 2/23/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/22/24 | 5/2/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 22,651 | 22,109 | 20,535 | - | - | 20,436 | 19,089 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 6.343 x | 6.712 x | 5.914 x | - | - | 6.527 x | 5.881 x | - |
| Free Cash Flow 1 | 1,231 | 809 | 1,157 | -946 | 817 | 1,041 | 1,348 | - |
| ROE (net income / shareholders' equity) | 82.1% | 179% | - | - | -665% | 642% | - | - |
| ROA (Net income/ Total Assets) | 4.7% | 4.39% | -3.14% | - | - | 0.2% | 1.6% | - |
| Assets 1 | -38,051 | -12,757 | 30,201 | - | - | 74,122 | 24,324 | - |
| Book Value Per Share 2 | 3.020 | 1.510 | - | - | - | -2.400 | -0.9300 | - |
| Cash Flow per Share 2 | 4.260 | 3.130 | 3.970 | -2.010 | 2.830 | 6.990 | 4.670 | - |
| Capex 1 | 270 | 302 | 269 | 218 | 215 | 256 | 218 | 206 |
| Capex / Sales | 3.14% | 3.76% | 3.19% | 2.68% | 2.46% | 2.73% | 2.25% | 2.06% |
| Announcement Date | 2/19/20 | 2/24/21 | 2/23/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
6.95
USD
Average target price
9.786
USD
Spread / Average Target
+40.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.34% | 2.55B | |
| +32.36% | 695B | |
| +26.51% | 568B | |
| -4.40% | 361B | |
| +19.46% | 330B | |
| +3.50% | 283B | |
| +16.87% | 239B | |
| +8.12% | 204B | |
| -7.44% | 198B | |
| +8.62% | 168B |
- Stock Market
- Equities
- BHC Stock
- Financials Bausch Health Companies Inc.